• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Canaccord Initiates Coverage, Issues 'Speculative Buy' Rating on MedReleaf

November 2, 2017

 (Photo Credit - Nick Youngson)


Canaccord Genuity's Matt Bottomley just issued a 'speculative buy' rating on shares of MedReleaf Corp. (TSX:LEAF) (OTC:MEDFF) alongside a price target of $15.00 CAD per share. MedReleaf currently has an average price target of $13.00 CAD per share, and out of the four analysts we track that cover MedReleaf, Bottomley's price target is the highest. 


With a last trade price of $13.03 CAR for shares of MedReleaf on the TSX, this price target represents over 15% potential upside.


Bottomley wrote, "“We are initiating coverage of MedReleaf Corp. with a SPECULATIVE BUY rating and a C$15.00 target price. We believe of the 69 licenses granted by Health Canada to over 50 companies, MedReleaf currently is an industry leader on several fronts, including (1) having likely the second-highest market share among Licensed Producers (LPs) at ~17%; (2) operating at one of the larger built capacities in the space at ~14,000 kg; (3) producing a leading assortment of product offerings; (4) being one of only a few Good Manufacturing Practices (GMP) licensed producers in Canada; and (5) perhaps most importantly, as one of the lowest-cost producers among indoor cultivators in Ontario with a cash cost of ~$1.50.”


Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, YouTube, and Instagram.



Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.